Precigen Stock Forecast, Price & News

Precigen (NASDAQ:PGEN) Frequently Asked Questions

Is Precigen a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Precigen stock.
View analyst ratings for Precigen or view top-rated stocks.

What stocks does MarketBeat like better than Precigen?

Wall Street analysts have given Precigen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Precigen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Precigen's next earnings date?

Precigen is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Precigen.

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) announced its earnings results on Monday, August, 9th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. The biotechnology company had revenue of $33.58 million for the quarter, compared to analysts' expectations of $22.48 million. Precigen had a negative trailing twelve-month return on equity of 70.74% and a negative net margin of 107.46%.
View Precigen's earnings history.

How has Precigen's stock price been impacted by COVID-19 (Coronavirus)?

Precigen's stock was trading at $2.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PGEN stock has increased by 89.1% and is now trading at $4.50.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for PGEN?

5 analysts have issued 12-month target prices for Precigen's shares. Their forecasts range from $10.00 to $14.00. On average, they expect Precigen's share price to reach $12.80 in the next twelve months. This suggests a possible upside of 184.4% from the stock's current price.
View analysts' price targets for Precigen or view top-rated stocks among Wall Street analysts.

Who are Precigen's key executives?

Precigen's management team includes the following people:

• Helen Sabzevari, President, Chief Executive Officer & Director (LinkedIn Profile)
• Rutul R. Shah, Head-Operations & Portfolio
• Harry Thomasian, Chief Financial Officer
• Thomas David Reed, Chief Science Officer
• Douglas E. Brough, Head-Research

Who are some of Precigen's key competitors?

Some companies that are related to Precigen include Cryoport (CYRX), Intra-Cellular Therapies (ITCI), Reata Pharmaceuticals (RETA), Zentalis Pharmaceuticals (ZNTL), Lyell Immunopharma (LYEL), Arena Pharmaceuticals (ARNA), Galapagos (GLPG), Hypera (HYPMY), Insmed (INSM), Prestige Consumer Healthcare (PBH), Nektar Therapeutics (NKTR), Cytokinetics (CYTK), ACADIA Pharmaceuticals (ACAD), Agios Pharmaceuticals (AGIO) and Apellis Pharmaceuticals (APLS).
View all of PGEN's competitors.

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), The Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).

What is Precigen's stock symbol?

Precigen trades on the NASDAQ under the ticker symbol "PGEN."

Who are Precigen's major shareholders?

Precigen's stock is owned by many different institutional and retail investors. Top institutional shareholders include New York State Teachers Retirement System (0.42%), Chiron Capital Management LLC (0.04%), Sanders Morris Harris LLC (0.02%) and Gateway Advisory LLC (0.01%). Company insiders that own Precigen stock include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rick L Sterling, Thomas Bostick and Trading SA Ares.
View institutional ownership trends for Precigen.

Which major investors are buying Precigen stock?

PGEN stock was bought by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, Gateway Advisory LLC, Sanders Morris Harris LLC, and Chiron Capital Management LLC. Company insiders that have bought Precigen stock in the last two years include Randal J Kirk, and Trading SA Ares.
View insider buying and selling activity for Precigen or or view top insider-buying stocks.

How do I buy shares of Precigen?

Shares of PGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precigen's stock price today?

One share of PGEN stock can currently be purchased for approximately $4.50.

How much money does Precigen make?

Precigen has a market capitalization of $929.89 million and generates $103.18 million in revenue each year. The biotechnology company earns $-170.52 million in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Precigen have?

Precigen employs 194 workers across the globe.

What is Precigen's official website?

The official website for Precigen is www.precigen.com.

Where are Precigen's headquarters?

Precigen is headquartered at 20374 Seneca Meadows Parkway, Germantown MD, 20876.

How can I contact Precigen?

Precigen's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at (301) 556-9900 or via email at [email protected].